US3026097A
(en)
|
1958-04-15 |
1962-03-20 |
Ball Charles Field |
Mining machine having laterally adjustable head
|
US4650764A
(en)
|
1983-04-12 |
1987-03-17 |
Wisconsin Alumni Research Foundation |
Helper cell
|
EP0173552B1
(en)
|
1984-08-24 |
1991-10-09 |
The Upjohn Company |
Recombinant dna compounds and the expression of polypeptides such as tpa
|
US5168062A
(en)
|
1985-01-30 |
1992-12-01 |
University Of Iowa Research Foundation |
Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
|
EP0273085A1
(en)
|
1986-12-29 |
1988-07-06 |
IntraCel Corporation |
A method for internalizing nucleic acids into eukaryotic cells
|
US4980289A
(en)
|
1987-04-27 |
1990-12-25 |
Wisconsin Alumni Research Foundation |
Promoter deficient retroviral vector
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
US5124263A
(en)
|
1989-01-12 |
1992-06-23 |
Wisconsin Alumni Research Foundation |
Recombination resistant retroviral helper cell and products produced thereby
|
US5399346A
(en)
|
1989-06-14 |
1995-03-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Gene therapy
|
US5550318A
(en)
|
1990-04-17 |
1996-08-27 |
Dekalb Genetics Corporation |
Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
|
US5071743A
(en)
|
1989-10-27 |
1991-12-10 |
Her Majesty The Queen In Right Of Canada, As Represented By The National Research Council Of Canada |
Process for conducting site-directed mutagenesis
|
US5484956A
(en)
|
1990-01-22 |
1996-01-16 |
Dekalb Genetics Corporation |
Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
|
US5384253A
(en)
|
1990-12-28 |
1995-01-24 |
Dekalb Genetics Corporation |
Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
|
AU2317192A
(en)
|
1991-07-01 |
1993-02-11 |
Berlex Laboratories, Inc. |
Novel mutagenesis methods and compositions
|
US5610042A
(en)
|
1991-10-07 |
1997-03-11 |
Ciba-Geigy Corporation |
Methods for stable transformation of wheat
|
GB9222888D0
(en)
|
1992-10-30 |
1992-12-16 |
British Tech Group |
Tomography
|
AU7477394A
(en)
|
1993-07-30 |
1995-03-27 |
University Of Medicine And Dentistry Of New Jersey |
Efficient gene transfer into primary lymphocytes
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
US5789166A
(en)
|
1995-12-08 |
1998-08-04 |
Stratagene |
Circular site-directed mutagenesis
|
EP0906420A1
(en)
|
1996-06-07 |
1999-04-07 |
Massachusetts Institute Of Technology |
Programmed sequential mutagenesis
|
US5780270A
(en)
|
1996-07-17 |
1998-07-14 |
Promega Corporation |
Site-specific mutagenesis and mutant selection utilizing antibiotic-resistant markers encoding gene products having altered substrate specificity
|
US7244826B1
(en)
|
1998-04-24 |
2007-07-17 |
The Regents Of The University Of California |
Internalizing ERB2 antibodies
|
US6693086B1
(en)
|
1998-06-25 |
2004-02-17 |
National Jewish Medical And Research Center |
Systemic immune activation method using nucleic acid-lipid complexes
|
EP1151012A4
(en)
|
1998-11-19 |
2003-01-08 |
Smithkline Beecham Corp |
ANTAGONIST ANTIBODIES OF RHAMM
|
WO2000034337A1
(en)
|
1998-12-10 |
2000-06-15 |
Tsukuba Research Laboratory, Toagosei Co., Ltd. |
Humanized monoclonal antibodies against vascular endothelial cell growth factor
|
IL129299A0
(en)
|
1999-03-31 |
2000-02-17 |
Mor Research Applic Ltd |
Monoclonal antibodies antigens and diagnosis of malignant diseases
|
US6342219B1
(en)
|
1999-04-28 |
2002-01-29 |
Board Of Regents, The University Of Texas System |
Antibody compositions for selectively inhibiting VEGF
|
US7312318B2
(en)
|
2002-03-01 |
2007-12-25 |
Immunomedics, Inc. |
Internalizing anti-CD74 antibodies and methods of use
|
US8383081B2
(en)
|
1999-05-10 |
2013-02-26 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods of use
|
US6949245B1
(en)
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
US6949520B1
(en)
|
1999-09-27 |
2005-09-27 |
Coley Pharmaceutical Group, Inc. |
Methods related to immunostimulatory nucleic acid-induced interferon
|
AU2001243288B2
(en)
|
2000-02-24 |
2005-11-24 |
Life Technologies Corporation |
Simultaneous stimulation and concentration of cells
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
US20040058445A1
(en)
|
2001-04-26 |
2004-03-25 |
Ledbetter Jeffrey Alan |
Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
|
DK1446162T3
(da)
|
2001-08-17 |
2008-12-08 |
Coley Pharm Gmbh |
Kombinationsmotiv-immunstimulatoriske oligonukleotider med forbedret aktivitet
|
US7306925B2
(en)
|
2001-11-09 |
2007-12-11 |
Vanderbilt University |
Phage antibodies to radiation-inducible neoantigens
|
DE60333554D1
(de)
|
2002-03-04 |
2010-09-09 |
Imclone Llc |
Kdr-spezifische humane antikörper und deren anwendung
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
AU2003248782A1
(en)
|
2002-07-01 |
2004-01-19 |
Biogen Idec Ma Inc. |
Humanized anti-lymphotoxin beta receptor antibodies
|
US20060057147A1
(en)
|
2002-10-04 |
2006-03-16 |
Mitsubishi Pharma Corporation |
Antibody recognizing antibody
|
US9068234B2
(en)
|
2003-01-21 |
2015-06-30 |
Ptc Therapeutics, Inc. |
Methods and agents for screening for compounds capable of modulating gene expression
|
EP1592713A2
(en)
|
2003-02-13 |
2005-11-09 |
Pharmacia Corporation |
Antibodies to c-met for the treatment of cancers
|
US7425328B2
(en)
|
2003-04-22 |
2008-09-16 |
Purdue Pharma L.P. |
Tissue factor antibodies and uses thereof
|
CA2532547C
(en)
|
2003-07-24 |
2020-02-25 |
Innate Pharma |
Methods and compositions for increasing the efficiency of therapeutic antibodies using nk cell potentiating compounds
|
US7902338B2
(en)
|
2003-07-31 |
2011-03-08 |
Immunomedics, Inc. |
Anti-CD19 antibodies
|
US7485297B2
(en)
|
2003-08-12 |
2009-02-03 |
Dyax Corp. |
Method of inhibition of vascular development using an antibody
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
CA2548787A1
(en)
|
2003-10-09 |
2005-04-21 |
Kyowa Hakko Kogyo Co., Ltd. |
Antibody composition specifically binding to ganglioside gm2
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
CA2552590A1
(en)
|
2004-01-05 |
2005-07-21 |
Emd Lexigen Research Center Corp. |
Interleukin-12 targeted to oncofoetal fibronectin
|
US7271245B2
(en)
|
2004-02-13 |
2007-09-18 |
The Scripps Research Institute |
Methods and compositions for inhibition of metastasis
|
AU2005250341A1
(en)
|
2004-04-23 |
2005-12-15 |
Amgen Inc. |
Antibodies to angiogenesis inhibiting domains of CD148
|
DK2921500T3
(da)
|
2004-07-10 |
2023-09-18 |
The Institute For Cancer Res |
Genetisk modificerede, humane, naturlige dræbercellelinjer
|
CA2575901C
(en)
|
2004-08-02 |
2015-01-27 |
Amrad Operations Pty. Ltd. |
A method of treating cancer comprising a vegf-b antagonist
|
US20060046294A1
(en)
|
2004-08-26 |
2006-03-02 |
The United States Of America, As Represented By The Secretary Of Agriculture |
Site-specific recombination systems for use in eukaryotic cells
|
US9034650B2
(en)
|
2005-02-02 |
2015-05-19 |
Intrexon Corporation |
Site-specific serine recombinases and methods of their use
|
JP5057967B2
(ja)
|
2005-03-31 |
2012-10-24 |
中外製薬株式会社 |
sc(Fv)2構造異性体
|
US9284375B2
(en)
|
2005-04-15 |
2016-03-15 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
US20070048325A1
(en)
|
2005-08-24 |
2007-03-01 |
Dennis Van Epps |
Combination therapies for inhibiting integrin-extracellular matrix interactions
|
TWI461436B
(zh)
|
2005-11-25 |
2014-11-21 |
Kyowa Hakko Kirin Co Ltd |
人類cd134(ox40)之人類單株抗體及其製造及使用方法
|
DOP2006000277A
(es)
|
2005-12-12 |
2007-08-31 |
Bayer Pharmaceuticals Corp |
Anticuerpos anti mn y métodos para su utilización
|
US20070160578A1
(en)
|
2005-12-14 |
2007-07-12 |
The Gov. Of The Usa As Represented By The Secretary Of The Dep. Of Health And Human Services |
Expansion of natural killer and CD8 T-cells with IL-15R/ligand activator complexes
|
PL1974020T3
(pl)
|
2005-12-16 |
2011-11-30 |
Ribovax Biotechnologies Sa |
Sposoby uzyskiwania unieśmiertelnionych komórek wydzielających przeciwciała
|
KR20090029184A
(ko)
|
2006-04-07 |
2009-03-20 |
더 가브먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
항체 조성물 및 신생물성 질병의 치료 방법
|
JP5622390B2
(ja)
|
2006-07-18 |
2014-11-12 |
サノフイ |
癌治療用対epha2アンタゴニスト抗体
|
SI2511301T1
(en)
|
2006-08-04 |
2018-05-31 |
MedImmune Limited, |
Human antibodies to ERBB 2
|
US9334330B2
(en)
|
2006-10-10 |
2016-05-10 |
Universite De Nantes |
Use of monoclonal antibodies specific to the O-acetylated form of GD2 ganglioside for the treatment of certain cancers
|
ATE504647T1
(de)
|
2007-01-30 |
2011-04-15 |
Forerunner Pharma Res Co Ltd |
Chimärer fc gamma rezeptor und verfahren zur bestimmung von adcc-aktivität unter verwendung des rezeptors
|
WO2008127735A1
(en)
|
2007-04-13 |
2008-10-23 |
Stemline Therapeutics, Inc. |
Il3ralpha antibody conjugates and uses thereof
|
WO2009030285A1
(en)
|
2007-09-07 |
2009-03-12 |
Ablynx N.V. |
Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
|
WO2009070753A2
(en)
|
2007-11-28 |
2009-06-04 |
The Scripps Research Institute |
Bivalent single chain fv antibody compositions that specifically bind to integrin receptor on a metastatic cell in a mammalian subject
|
CA2710471C
(en)
|
2007-12-26 |
2018-06-05 |
Biotest Ag |
Immunoconjugates targeting cd138 and uses thereof
|
EP2274008B1
(en)
|
2008-03-27 |
2014-02-26 |
ZymoGenetics, Inc. |
Compositions and methods for inhibiting pdgfrbeta and vegf-a
|
JP2011518128A
(ja)
|
2008-04-02 |
2011-06-23 |
アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツング |
腫瘍、炎症性障害および免疫障害の治療のためのil−4受容体に対する結合剤
|
US8530636B2
(en)
|
2008-05-07 |
2013-09-10 |
The Board Of Trustees Of The Leland Stanford Junior University |
Method for regulating protein function in cells in vivo using synthetic small molecules
|
US20100008978A1
(en)
|
2008-05-09 |
2010-01-14 |
The Regents Of The University Of California |
Nanoparticles effective for internalization into cells
|
JP5792621B2
(ja)
|
2008-09-26 |
2015-10-14 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
frizzled結合剤およびその使用
|
SI2342226T1
(sl)
|
2008-09-26 |
2016-11-30 |
Dana-Farber Cancer Institute Inc. |
Humana protitelesa proti PD-1, PD-L1 in PD-L2 in njihove uporabe
|
EP2172485A1
(en)
|
2008-10-01 |
2010-04-07 |
Pierre Fabre Medicament |
Novel anti CXCR4 antibodies and their use for the treatment of cancer
|
BRPI0921586A2
(pt)
|
2008-11-18 |
2019-09-24 |
Merrimack Pharmaceuticals Inc |
articuladores de albumina de soro humana e conjugados destes
|
US20110293620A1
(en)
|
2008-12-05 |
2011-12-01 |
Molldrem Jeffrey J |
Monoclonal Antibodies For Use In Diagnosis and Therapy of Cancers and Autoimmune Disease
|
AU2010216152B2
(en)
|
2009-02-17 |
2015-05-14 |
Ucb Biopharma Sprl |
Antibody molecules having specificity for human OX40
|
GB0903325D0
(en)
|
2009-02-26 |
2009-04-08 |
Univ Aberdeen |
Antibody molecules
|
WO2010107658A2
(en)
|
2009-03-16 |
2010-09-23 |
Vallera Daniel A |
Methods and compositions for bi-specific targeting of cd19/cd22
|
HUE025726T2
(en)
|
2009-03-25 |
2016-04-28 |
Genentech Inc |
Anti-FGFR3 antibodies and their use
|
PL2411507T3
(pl)
|
2009-03-26 |
2020-07-13 |
Cellprotect Nordic Pharmaceuticals Ab |
Namnażanie komórek nk
|
TWI529247B
(zh)
|
2009-05-13 |
2016-04-11 |
建新公司 |
抗人類cd52免疫球蛋白
|
US8221753B2
(en)
|
2009-09-30 |
2012-07-17 |
Tracon Pharmaceuticals, Inc. |
Endoglin antibodies
|
CN102482701B
(zh)
|
2009-09-16 |
2015-05-13 |
免疫医疗公司 |
I类抗-cea抗体及其使用
|
JP5934099B2
(ja)
|
2009-10-01 |
2016-06-15 |
アメリカ合衆国 |
抗血管内皮増殖因子受容体−2キメラ抗原受容体及び癌の治療のためのその使用
|
ES2646863T3
(es)
|
2009-11-24 |
2017-12-18 |
Medimmune Limited |
Agentes de unión específica contra B7-H1
|
WO2011069019A2
(en)
|
2009-12-02 |
2011-06-09 |
David Ho |
J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
|
CN102753195A
(zh)
|
2009-12-07 |
2012-10-24 |
小利兰·斯坦福大学托管委员会 |
用于增强抗肿瘤抗体疗法的方法
|
US20130011376A1
(en)
|
2009-12-29 |
2013-01-10 |
Gamida Cell Ltd. |
Methods for Enhancing Natural Killer Cell Proliferation and Activity
|
CN103370080A
(zh)
|
2010-02-04 |
2013-10-23 |
吉联亚生物科技有限公司 |
结合赖氨酰氧化酶样2(loxl2)的抗体和其使用方法
|
WO2011116212A2
(en)
|
2010-03-17 |
2011-09-22 |
Oncomed Pharmaceuticals, Inc. |
Bone morphogenetic protein receptor binding agents and methods of their use
|
DK2552959T3
(en)
|
2010-03-26 |
2017-05-01 |
Memorial Sloan Kettering Cancer Center |
ANTIBODIES FOR MUC16 AND PROCEDURES FOR USE THEREOF
|
PT3202789T
(pt)
|
2010-04-16 |
2020-06-16 |
Biogen Ma Inc |
Anticorpos anti-vla-4
|
US9242014B2
(en)
|
2010-06-15 |
2016-01-26 |
The Regents Of The University Of California |
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
|
CA2801210C
(en)
|
2010-06-19 |
2020-07-21 |
Memorial Sloan-Kettering Cancer Center |
Anti-gd2 antibodies
|
KR20210063457A
(ko)
|
2010-07-13 |
2021-06-01 |
안트로제네시스 코포레이션 |
천연 킬러 세포의 생성 방법
|
EP2407487A1
(en)
|
2010-07-14 |
2012-01-18 |
F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. |
Multispecific modular antibody
|
WO2012019061A2
(en)
|
2010-08-05 |
2012-02-09 |
Stem Centrx, Inc. |
Novel effectors and methods of use
|
MX2013002255A
(es)
|
2010-08-27 |
2013-07-03 |
Stem Centrx Inc |
Moduladores de proteina de notum y metodos de uso.
|
WO2012031273A2
(en)
|
2010-09-03 |
2012-03-08 |
Stem Centrx, Inc. |
Novel modulators and methods of use
|
EP2918607B1
(en)
|
2010-09-21 |
2017-11-08 |
Altor BioScience Corporation |
Multimeric il-15 soluble fusion molecules and methods of making and using same
|
US9845362B2
(en)
|
2010-10-08 |
2017-12-19 |
The University Of North Carolina At Charlotte |
Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
|
CA2818635C
(en)
|
2010-12-06 |
2021-06-15 |
National Reseach Council Of Canada |
Antibodies selective for cells presenting erbb2 at high density
|
RU2016123839A
(ru)
|
2010-12-08 |
2018-11-30 |
АббВай Стемсентркс ЭлЭлСи |
Новые модуляторы и способы их применения
|
PL3214091T3
(pl)
|
2010-12-09 |
2019-03-29 |
The Trustees Of The University Of Pennsylvania |
Zastosowanie komórek T modyfikowanych chimerycznymi receptorami antygenowymi do leczenia nowotworów
|
AU2011343887B2
(en)
|
2010-12-14 |
2016-06-16 |
University Of Maryland, Baltimore |
Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer
|
EA201391059A1
(ru)
|
2011-01-18 |
2014-05-30 |
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания |
Композиции для лечения рака и способы их применения
|
WO2012099093A1
(ja)
|
2011-01-21 |
2012-07-26 |
株式会社日本バイオセラピー研究所 |
Nk細胞強化型血液製剤の製造方法
|
SA112330278B1
(ar)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
مواد ضابطة جديدة وطرق للاستخدام
|
GB201103955D0
(en)
|
2011-03-09 |
2011-04-20 |
Antitope Ltd |
Antibodies
|
SI2694549T1
(sl)
|
2011-04-08 |
2018-12-31 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Himerni antigenski receptorji varianta III receptorja anti-epidermalnega rastnega faktorja in uporaba le-tega za zdravljenje raka
|
CN105968209B
(zh)
|
2011-04-19 |
2021-08-03 |
美国政府(由卫生和人类服务部的部长所代表) |
对磷脂酰肌醇蛋白聚糖3特异的人单克隆抗体及其用途
|
WO2012145384A1
(en)
|
2011-04-20 |
2012-10-26 |
University Of Washington Through Its Center For Commercialization |
Beta-2 microglobulin-deficient cells
|
CA2833019A1
(en)
|
2011-04-22 |
2012-10-26 |
Emergent Product Development Seattle, Llc |
Prostate-specific membrane antigen binding proteins and related compositions and methods
|
JP5572863B2
(ja)
|
2011-06-24 |
2014-08-20 |
国立大学法人九州大学 |
Nk細胞の増幅方法
|
US8841418B2
(en)
|
2011-07-01 |
2014-09-23 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to TIM3
|
MX353931B
(es)
|
2011-07-11 |
2018-02-02 |
Glenmark Pharmaceuticals Sa |
Anticuerpos que se unen a ox40 y sus usos.
|
RU2604814C2
(ru)
|
2011-07-24 |
2016-12-10 |
Кьюртек Лтд. |
Варианты гуманизированных иммуномодулирующих моноклональных антител
|
WO2013023162A2
(en)
|
2011-08-10 |
2013-02-14 |
Genus Oncology, Llc |
Anti-muc1 antibodies for cancer diagnostics
|
WO2013033626A2
(en)
|
2011-08-31 |
2013-03-07 |
Trustees Of Dartmouth College |
Nkp30 receptor targeted therapeutics
|
AU2012318541B2
(en)
|
2011-10-06 |
2018-04-12 |
Aveo Pharmaceuticals, Inc. |
Predicting tumor response to anti-ERBB3 antibodies
|
WO2013051718A1
(ja)
|
2011-10-07 |
2013-04-11 |
国立大学法人三重大学 |
キメラ抗原受容体
|
AU2012325915A1
(en)
|
2011-10-20 |
2014-04-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-CD22 chimeric antigen receptors
|
US9272002B2
(en)
|
2011-10-28 |
2016-03-01 |
The Trustees Of The University Of Pennsylvania |
Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
|
US9422351B2
(en)
|
2011-11-03 |
2016-08-23 |
The Trustees Of The University Of Pennsylvania |
Isolated B7-H4 specific compositions and methods of use thereof
|
WO2013074596A1
(en)
|
2011-11-16 |
2013-05-23 |
Oncomed Pharmaceuticals, Inc. |
Human notch receptor mutations and their use
|
WO2013074916A1
(en)
|
2011-11-18 |
2013-05-23 |
Board Of Regents, The University Of Texas System |
Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
|
EP2788020A4
(en)
|
2011-12-05 |
2015-04-29 |
Immunomedics Inc |
THERAPEUTIC USE OF ANTI-CD22 ANTIBODIES FOR THE INDUCTION OF TROGO CYTOSIS
|
US9757458B2
(en)
|
2011-12-05 |
2017-09-12 |
Immunomedics, Inc. |
Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
|
KR101644984B1
(ko)
|
2011-12-22 |
2016-08-12 |
재단법인 목암생명과학연구소 |
자연살해세포의 제조방법, 이러한 방법에 의해 제조된 자연살해세포 및 이를 포함하는 종양 및 감염성 질환 치료용 조성물
|
JP2015509085A
(ja)
|
2012-01-01 |
2015-03-26 |
キュービーアイ エンタープライゼズ リミテッドQbi Enterprises Ltd. |
治療剤および診断剤の選択的送達のためのendo180を標的とする粒子
|
MX363819B
(es)
|
2012-02-08 |
2019-04-03 |
Igm Biosciences Inc |
Uniones a cdim y sus usos.
|
US9534058B2
(en)
|
2012-02-08 |
2017-01-03 |
Abbvie Stemcentrx Llc |
Anti-CD324 monoclonal antibodies and uses thereof
|
AU2013221672B2
(en)
|
2012-02-13 |
2017-11-09 |
Seattle Children's Hospital D/B/A Seattle Children's Research Institute |
Bispecific chimeric antigen receptors and therapeutic uses thereof
|
RU2014138474A
(ru)
|
2012-02-24 |
2016-04-10 |
СтемСентРкс, Инк. |
Новые модуляторы и способы применения
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
CA3209571A1
(en)
|
2012-03-23 |
2013-09-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin chimeric antigen receptors
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
KR102229945B1
(ko)
|
2012-04-11 |
2021-03-18 |
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
B-세포 성숙 항원을 표적화하는 키메라 항원 수용체
|
EP2838548B1
(en)
|
2012-04-17 |
2023-07-19 |
University of Washington through its Center for Commercialization |
Hla class ii deficient cells, hla class i deficient cells capable of expressing hla class ii proteins, and uses thereof
|
US9156915B2
(en)
|
2012-04-26 |
2015-10-13 |
Thomas Jefferson University |
Anti-GCC antibody molecules
|
KR101505157B1
(ko)
|
2012-05-08 |
2015-03-24 |
주식회사 종근당 |
항―ErbB2 항체 변이체
|
PL2855667T3
(pl)
|
2012-05-25 |
2024-03-25 |
Cellectis |
Sposoby uzyskiwania metodami inżynierii allogenicznych i opornych na immunosupresję limfocytów t do immunoterapii
|
US20150017136A1
(en)
|
2013-07-15 |
2015-01-15 |
Cellectis |
Methods for engineering allogeneic and highly active t cell for immunotherapy
|
SG11201407972RA
(en)
|
2012-06-01 |
2015-01-29 |
Us Health |
High-affinity monoclonal antibodies to glypican-3 and use thereof
|
US20150202286A1
(en)
|
2012-07-13 |
2015-07-23 |
The Children's Hospital of Philadelphai |
Toxicity Management for Anti-Tumor Activity of CARs
|
EP2888282B1
(en)
|
2012-08-21 |
2018-03-14 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Mesothelin domain-specific monoclonal antibodies and use thereof
|
UA115789C2
(uk)
|
2012-09-05 |
2017-12-26 |
Трейкон Фармасутікалз, Інк. |
Композиція антитіла до cd105 та її застосування
|
TW201922795A
(zh)
|
2012-09-10 |
2019-06-16 |
愛爾蘭商尼歐托普生物科學公司 |
抗mcam抗體及相關使用方法
|
US9416190B2
(en)
|
2012-09-27 |
2016-08-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Mesothelin antibodies and methods for eliciting potent antitumor activity
|
AR092745A1
(es)
|
2012-10-01 |
2015-04-29 |
Univ Pennsylvania |
Composiciones que comprenden un dominio de union anti-fap y metodos para hacer blanco en celulas estromales para el tratamiento del cancer
|
SI2904011T1
(sl)
|
2012-10-02 |
2017-10-30 |
Bristol-Myers Squibb Company |
Kombinacija anti-kir protiteles in anti-pd-1 protiteles za zdravljenje raka
|
WO2014055668A1
(en)
|
2012-10-02 |
2014-04-10 |
Memorial Sloan-Kettering Cancer Center |
Compositions and methods for immunotherapy
|
EP2912063A1
(en)
|
2012-10-23 |
2015-09-02 |
Bristol-Myers Squibb Company |
Combination of anti-kir and anti-ctla-4 antibodies to treat cancer
|
CN104822705B
(zh)
|
2012-10-24 |
2019-07-12 |
美国卫生和人力服务部 |
M971嵌合抗原受体
|
WO2014085821A2
(en)
|
2012-11-30 |
2014-06-05 |
The Regents Of The University Of California |
Fully human antibodies and fragments recognizing human c-met
|
US9574013B2
(en)
|
2012-12-07 |
2017-02-21 |
Vanderbilt University |
Antibodies against factor XII and uses thereof
|
EP2948544A4
(en)
|
2013-01-28 |
2016-08-03 |
St Jude Childrens Res Hospital |
CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES
|
DK2958943T3
(da)
|
2013-02-20 |
2019-12-09 |
Univ Pennsylvania |
Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor
|
SI2968588T1
(sl)
|
2013-03-15 |
2019-05-31 |
AbbVie Deutschland GmbH & Co. KG |
Formulacije konjugatov protitelo proti-EGFR zdravilo
|
US9446105B2
(en)
|
2013-03-15 |
2016-09-20 |
The Trustees Of The University Of Pennsylvania |
Chimeric antigen receptor specific for folate receptor β
|
US20140302037A1
(en)
|
2013-03-15 |
2014-10-09 |
Amgen Inc. |
BISPECIFIC-Fc MOLECULES
|
US9657105B2
(en)
|
2013-03-15 |
2017-05-23 |
City Of Hope |
CD123-specific chimeric antigen receptor redirected T cells and methods of their use
|
EP4098275A1
(en)
|
2013-03-15 |
2022-12-07 |
Memorial Sloan-Kettering Cancer Center |
Compositions and methods for immunotherapy
|
TWI654206B
(zh)
|
2013-03-16 |
2019-03-21 |
諾華公司 |
使用人類化抗-cd19嵌合抗原受體治療癌症
|
WO2014160627A1
(en)
|
2013-03-25 |
2014-10-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-cd276 polypeptides, proteins, and chimeric antigen receptors
|
EP3789487A1
(en)
|
2013-04-03 |
2021-03-10 |
Memorial Sloan Kettering Cancer Center |
Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
|
DK2986635T3
(en)
|
2013-04-18 |
2019-01-28 |
Fond Telethon |
EFFECTIVE DELIVERY OF BIG GENES THROUGH DUAL-AAV VECTORS
|
ES2777940T3
(es)
|
2013-05-03 |
2020-08-06 |
Ohio State Innovation Foundation |
Células efectoras inmunitarias genomanipuladas con un receptor de antígeno químico específico de CS1
|
CN104140974B
(zh)
|
2013-05-08 |
2017-09-29 |
科济生物医药(上海)有限公司 |
编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
|
US10077312B2
(en)
|
2013-05-10 |
2018-09-18 |
Numab Therapeutics AG |
CD3 and IL-23 receptor binding bispecific constructs and their use in the treatment of various diseases
|
CA2912375C
(en)
|
2013-05-13 |
2023-03-14 |
Cellectis |
Methods for engineering highly active t cell for immunotherapy
|
FI2997141T3
(fi)
|
2013-05-13 |
2022-12-15 |
|
CD19-spesifinen kimeerinen antigeenireseptori ja sen käyttöjä
|
US11311575B2
(en)
|
2013-05-13 |
2022-04-26 |
Cellectis |
Methods for engineering highly active T cell for immunotherapy
|
WO2014186469A2
(en)
|
2013-05-14 |
2014-11-20 |
Board Of Regents, The University Of Texas System |
Human application of engineered chimeric antigen receptor (car) t-cells
|
ES2883131T3
(es)
|
2013-05-29 |
2021-12-07 |
Cellectis |
Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN
|
ES2791598T3
(es)
|
2013-06-05 |
2020-11-05 |
Bellicum Pharmaceuticals Inc |
Métodos para inducir apoptosis parcial utilizando polipéptidos de caspasa
|
JP6611709B2
(ja)
|
2013-06-25 |
2019-11-27 |
バクシネックス インコーポレーティッド |
腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン−4d阻害分子の使用
|
CA2915882C
(en)
|
2013-06-27 |
2022-12-06 |
Monash University |
Il-21 binding proteins and uses thereof
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
WO2015017755A1
(en)
|
2013-08-02 |
2015-02-05 |
The Regents Of The University Of California |
Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
|
CN105940102B
(zh)
|
2013-08-26 |
2020-02-18 |
海瑞克·亚柏坎 |
抗cd30嵌合抗原受体及其用途
|
DE102013109611A1
(de)
|
2013-09-03 |
2015-03-05 |
Maschinenfabrik Reinhausen Gmbh |
Vorrichtung und Verfahren zur Steuerung der Stabilität eines Ortsnetzes mit einem regelbaren Ortsnetztransformator
|
EP3048112B1
(en)
|
2013-09-18 |
2020-03-11 |
Tosoh Corporation |
Fc-BINDING PROTEIN, METHOD FOR PRODUCING SAID PROTEIN, AND ANTIBODY ADSORBENT USING SAID PROTEIN, AND METHODS FOR PURIFYING AND IDENTIFYING ANTIBODY USING SAID ADSORBENT
|
HUE062317T2
(hu)
|
2013-09-20 |
2023-10-28 |
Bristol Myers Squibb Co |
Anti-LAG-3 antitestek és anti-PD-1 antitestek kombinációja tumorok kezeléséhez
|
EA201991715A1
(ru)
|
2013-09-27 |
2020-03-31 |
Дженентек, Инк. |
Композиции, содержащие антитело к pdl1
|
CA2926428C
(en)
|
2013-10-09 |
2023-08-29 |
Research Development Foundation |
Monoclonal olfml-3 antibodies and uses thereof
|
GB201317929D0
(en)
|
2013-10-10 |
2013-11-27 |
Ucl Business Plc |
Chimeric antigen receptor
|
WO2015054691A2
(en)
|
2013-10-11 |
2015-04-16 |
The United States Of America, As Pepresented By The Secretary, Department Of Health And Human Services |
Tem8 antibodies and their use
|
JP6734774B2
(ja)
|
2013-10-15 |
2020-08-05 |
ザ スクリプス リサーチ インスティテュート |
ペプチドキメラ抗原受容体t細胞スイッチおよびその使用
|
US20150238631A1
(en)
|
2013-10-15 |
2015-08-27 |
The California Institute For Biomedical Research |
Chimeric antigen receptor t cell switches and uses thereof
|
US10144770B2
(en)
|
2013-10-17 |
2018-12-04 |
National University Of Singapore |
Chimeric receptors and uses thereof in immune therapy
|
MX2016005689A
(es)
|
2013-10-31 |
2016-08-08 |
Hutchinson Fred Cancer Res |
Celulas no t efectoras y madre/progenitoras hematopoyeticas modificadas y usos de estas.
|
EP3065780A1
(en)
|
2013-11-04 |
2016-09-14 |
Pfizer Inc. |
Anti-efna4 antibody-drug conjugates
|
EP3066118B1
(en)
|
2013-11-06 |
2020-01-08 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Alk antibodies, conjugates, and chimeric antigen receptors, and their use
|
EP3066130B1
(en)
|
2013-11-07 |
2019-05-15 |
Memorial Sloan-Kettering Cancer Center |
Anti-wt1/hla bi-specific antibody
|
WO2015073575A2
(en)
|
2013-11-12 |
2015-05-21 |
Centre For Probe Development And Commercialization |
Residualizing linkers and uses thereof
|
US9932607B2
(en)
|
2013-11-15 |
2018-04-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Site-specific integration of transgenes into human cells
|
EP3858378A1
(en)
|
2013-11-21 |
2021-08-04 |
Autolus Limited |
Cell
|
CN105765061A
(zh)
|
2013-11-22 |
2016-07-13 |
塞勒克提斯公司 |
工程化耐受化疗药物的t-细胞用于免疫治疗的方法
|
EP3071686B1
(en)
|
2013-11-22 |
2020-07-22 |
Cellectis SA |
Method for generating batches of allogeneic t-cells with averaged potency
|
US10246505B2
(en)
|
2013-11-25 |
2019-04-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptors to control HIV infection
|
US20160376375A1
(en)
|
2013-11-27 |
2016-12-29 |
Baylor College Of Medicine |
CSGP4 - Specific Chimeric Antigen Receptor for Cancer
|
JP6943568B2
(ja)
|
2013-12-06 |
2021-10-06 |
アメリカ合衆国 |
胸腺間質性リンパ球新生因子受容体特異的キメラ抗原受容体及びそれを使用する方法
|
CN106102774A
(zh)
|
2013-12-17 |
2016-11-09 |
豪夫迈·罗氏有限公司 |
包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法
|
CA3225453A1
(en)
|
2013-12-19 |
2015-06-25 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
CN105611944A
(zh)
|
2013-12-20 |
2016-05-25 |
豪夫迈·罗氏有限公司 |
抗ang2抗体和cd40激动剂的组合疗法
|
EP3808410A1
(en)
|
2013-12-20 |
2021-04-21 |
Cellectis |
Method of engineering multi-input signal sensitive t cell for immunotherapy
|
US10287354B2
(en)
|
2013-12-20 |
2019-05-14 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
KR102483822B1
(ko)
|
2013-12-20 |
2023-01-03 |
프레드 허친슨 캔서 센터 |
태그된 키메라 이펙터 분자 및 그의 리셉터
|
WO2015097536A2
(en)
|
2013-12-24 |
2015-07-02 |
Janssen Pharmaceutical Nv |
Anti-vista antibodies and fragments
|
US10010625B2
(en)
*
|
2014-01-02 |
2018-07-03 |
The Johns Hopkins University |
Antimicrobial compositions comprising single domain antibodies and pseudomonas exotoxin
|
CN113307880A
(zh)
|
2014-01-13 |
2021-08-27 |
希望之城公司 |
在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法
|
WO2015107075A1
(en)
|
2014-01-14 |
2015-07-23 |
Cellectis |
Chimeric antigen receptor using antigen recognition domains derived from cartilaginous fish
|
WO2015112626A1
(en)
|
2014-01-21 |
2015-07-30 |
June Carl H |
Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
EP3097123A1
(en)
|
2014-01-24 |
2016-11-30 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Anti-ny-br-1 polypeptides, proteins, and chimeric antigen receptors
|
EP3099706B1
(en)
|
2014-01-29 |
2018-10-31 |
BioNTech AG |
Peptide mimotopes of claudin 18.2 and uses thereof
|
CN106132992B
(zh)
|
2014-01-29 |
2020-08-07 |
达娜-法勃肿瘤研究所公司 |
针对muc1-c/胞外结构域(muc1-c/ecd)的抗体
|
WO2015120180A1
(en)
|
2014-02-05 |
2015-08-13 |
The University Of Chicago |
Chimeric antigen receptors recognizing cancer-specific tn glycopeptide variants
|
GB201402006D0
(en)
|
2014-02-06 |
2014-03-26 |
Oncomatryx Biopharma S L |
Antibody-drug conjugates and immunotoxins
|
EP3105317B1
(en)
|
2014-02-14 |
2018-09-19 |
Cellectis |
Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
|
JP6665102B2
(ja)
|
2014-02-21 |
2020-03-13 |
セレクティスCellectis |
制御性t細胞をインサイチューで阻害するための方法
|
WO2015130416A1
(en)
|
2014-02-25 |
2015-09-03 |
Immunomedics, Inc. |
Humanized rfb4 anti-cd22 antibody
|
KR101605421B1
(ko)
|
2014-03-05 |
2016-03-23 |
국립암센터 |
B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도
|
GB201403972D0
(en)
|
2014-03-06 |
2014-04-23 |
Ucl Business Plc |
Chimeric antigen receptor
|
JP6632984B2
(ja)
|
2014-03-11 |
2020-01-22 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
抗EGFRvIII抗体およびその使用
|
WO2015136001A1
(en)
|
2014-03-11 |
2015-09-17 |
Cellectis |
Method for generating t-cells compatible for allogenic transplantation
|
TW201623331A
(zh)
|
2014-03-12 |
2016-07-01 |
普羅帝納生物科學公司 |
抗黑色素瘤細胞黏著分子(mcam)抗體類及使用彼等之相關方法
|
CU24481B1
(es)
|
2014-03-14 |
2020-03-04 |
Immutep Sas |
Moléculas de anticuerpo que se unen a lag-3
|
US20170335281A1
(en)
|
2014-03-15 |
2017-11-23 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
DK3119807T3
(da)
|
2014-03-19 |
2019-07-15 |
Cellectis |
Cd123-specifikke kimære antigenreceptorer til cancerimmunterapi
|
UY36041A
(es)
|
2014-03-21 |
2015-09-30 |
Abbvie Inc |
Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
|
AU2015235852B2
(en)
|
2014-03-28 |
2019-08-15 |
Regents Of The University Of Minnesota |
Polypeptides, cells, and methods involving engineered CD16
|
US9944702B2
(en)
|
2014-04-03 |
2018-04-17 |
Cellectis |
CD33 specific chimeric antigen receptors for cancer immunotherapy
|
PL3560954T3
(pl)
|
2014-04-03 |
2021-12-13 |
Igm Biosciences, Inc. |
Zmodyfikowany łańcuch J
|
SG10202109752XA
(en)
|
2014-04-07 |
2021-10-28 |
Novartis Ag |
Treatment of cancer using anti-cd19 chimeric antigen receptor
|
CN106573969B
(zh)
|
2014-04-10 |
2021-07-30 |
西雅图儿童医院(Dba西雅图儿童研究所) |
药物相关的转基因表达
|
JP2017513472A
(ja)
|
2014-04-11 |
2017-06-01 |
セレクティスCellectis |
アルギニンおよび/またはトリプトファン枯渇微小環境に対して抵抗性を有する免疫細胞を作製するための方法
|
EP3131927B8
(en)
|
2014-04-14 |
2020-12-23 |
Cellectis |
Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
|
MY184699A
(en)
|
2014-04-16 |
2021-04-18 |
Juno Therapeutics Gmbh |
Methods, kits and apparatus for expanding a population of cells
|
US9777070B2
(en)
|
2014-04-30 |
2017-10-03 |
Pfizer Inc |
Anti-PTK7 antibody-drug conjugates
|
EA201692109A1
(ru)
|
2014-05-01 |
2017-03-31 |
Дженентек, Инк. |
Варианты антител к фактору d и их применение
|
AU2015254595B2
(en)
|
2014-05-02 |
2019-06-27 |
Cellectis |
CS1 specific multi-chain chimeric antigen receptor
|
ES2839089T3
(es)
|
2014-05-15 |
2021-07-05 |
Nat Univ Singapore |
Linfocitos citolíticos naturales modificados y usos de los mismos
|
US11041021B2
(en)
|
2014-05-23 |
2021-06-22 |
University Of Florida Research Foundation, Incorporated |
Car based immunotherapy
|
CA2951045A1
(en)
|
2014-06-02 |
2015-12-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptors targeting cd-19
|
EP3151854B1
(en)
|
2014-06-06 |
2020-02-26 |
Memorial Sloan Kettering Cancer Center |
Mesothelin-targeted chimeric antigen receptors and uses thereof
|
US20170121419A1
(en)
|
2014-06-12 |
2017-05-04 |
The General Hospital Corporation |
Anti-human Chemokine (C-C motif) Receptor 4 Immunotoxins
|
WO2015200073A1
(en)
|
2014-06-23 |
2015-12-30 |
Bionomics, Inc. |
Antibodies that bind lgr4
|
EP3169703B2
(en)
|
2014-07-16 |
2023-12-13 |
Hinrich Abken |
Chimeric antigen receptor and its use
|
EP3172237A2
(en)
|
2014-07-21 |
2017-05-31 |
Novartis AG |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
AU2015292755B2
(en)
|
2014-07-21 |
2020-11-12 |
Novartis Ag |
Treatment of cancer using a CD33 chimeric antigen receptor
|
WO2016014535A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Treatment of cancer using a cll-1 chimeric antigen receptor
|
SG10201900455YA
(en)
|
2014-07-24 |
2019-02-27 |
Bluebird Bio Inc |
Bcma chimeric antigen receptors
|
US10519248B2
(en)
|
2014-07-25 |
2019-12-31 |
Memorial Sloan Kettering Cancer Center |
Bispecific HER2 and CD3 binding molecules
|
KR20180125632A
(ko)
|
2014-07-29 |
2018-11-23 |
화이자 인코포레이티드 |
암 면역요법을 위한 EGFRvIII 특이적 키메라 항원 수용체
|
DK3453406T3
(da)
|
2014-07-29 |
2021-07-12 |
Cellectis |
ROR1(NTRKR1)-specifikke kimære antigenreceptorer til cancerimmunterapi
|
EP3194432B1
(en)
|
2014-07-31 |
2019-04-10 |
Cellectis |
Ror1 specific multi-chain chimeric antigen receptor
|
TWI542139B
(zh)
|
2014-07-31 |
2016-07-11 |
瑞昱半導體股份有限公司 |
數位預失真電路與方法以及數位預失真訓練電路
|
GB201413913D0
(en)
|
2014-08-06 |
2014-09-17 |
Cantargia Ab |
Novel antibodies and uses thereof
|
WO2016022939A1
(en)
|
2014-08-08 |
2016-02-11 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Human monoclonal antibodies specific for 5t4 and methods of their use
|
CN106661129B
(zh)
|
2014-08-19 |
2021-02-05 |
美天施生物科技有限两合公司 |
对ssea4抗原具有特异性的嵌合抗原受体
|
MA40475A
(fr)
|
2014-08-19 |
2017-06-28 |
Fayadat Dilman Laurence |
Anticorps anti-tigit
|
MY189028A
(en)
|
2014-08-19 |
2022-01-20 |
Novartis Ag |
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
|
EP3186277B1
(en)
|
2014-08-27 |
2020-10-07 |
Memorial Sloan Kettering Cancer Center |
Antibodies, compositions, and uses
|
TWI751102B
(zh)
|
2014-08-28 |
2022-01-01 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
ES2688035T3
(es)
|
2014-08-29 |
2018-10-30 |
Gemoab Monoclonals Gmbh |
Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
|
JP6810685B2
(ja)
|
2014-09-04 |
2021-01-06 |
セレクティスCellectis |
癌免疫療法のための栄養膜糖タンパク質(5t4、tpbg)特異的キメラ抗原受容体
|
KR20170058960A
(ko)
|
2014-09-09 |
2017-05-29 |
보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 |
Agr2 및 그의 수용체 c4.4a 에 대한 차단 모노클로날 항체
|
CN106804108B
(zh)
|
2014-09-12 |
2021-08-10 |
基因泰克公司 |
抗-b7-h4抗体及免疫缀合物
|
EA201790545A1
(ru)
|
2014-09-12 |
2017-07-31 |
Дженентек, Инк. |
Антитела и иммуноконъюгаты против her2
|
AR101846A1
(es)
|
2014-09-12 |
2017-01-18 |
Genentech Inc |
Anticuerpos anti-cll-1 e inmunoconjugados
|
EP3191524A4
(en)
|
2014-09-12 |
2018-05-30 |
The Regents of The University of California |
Macropinocytosing human anti-cd46 antibodies and targeted cancer therapeutics
|
US9993551B2
(en)
|
2014-09-13 |
2018-06-12 |
Novartis Ag |
Combination therapies of EGFR inhibitors
|
RU2745705C2
(ru)
|
2014-09-15 |
2021-03-30 |
МОЛМЕД СпА |
Химерные рецепторы антигенов
|
KR20170068458A
(ko)
|
2014-09-16 |
2017-06-19 |
이나뜨 파르마, 에스.아. |
항-nkg2a 항체를 사용한 치료 요법
|
JP6613304B2
(ja)
|
2014-09-17 |
2019-12-04 |
ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
抗cd276抗体(b7h3)
|
EP3587446A1
(en)
|
2014-09-19 |
2020-01-01 |
City of Hope |
Costimulatory chimeric antigen receptor t cells targeting il13 r alpha 2
|
ES2844700T3
(es)
|
2014-09-26 |
2021-07-22 |
Baylor College Medicine |
Receptores quiméricos de antígeno específicos de glipicano-3 para inmunoterapia adoptiva
|
KR102390359B1
(ko)
|
2014-09-29 |
2022-04-22 |
삼성전자주식회사 |
폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체
|
KR20170066546A
(ko)
|
2014-10-03 |
2017-06-14 |
노파르티스 아게 |
조합 요법
|
EP3204491A1
(en)
|
2014-10-07 |
2017-08-16 |
Cellectis |
Method for modulating car-induced immune cells activity
|
BR112017006464A2
(pt)
|
2014-10-10 |
2018-01-30 |
Innate Pharma |
bloqueio de cd73
|
TW201619200A
(zh)
|
2014-10-10 |
2016-06-01 |
麥迪紐有限責任公司 |
人類化抗-ox40抗體及其用途
|
TWI716362B
(zh)
|
2014-10-14 |
2021-01-21 |
瑞士商諾華公司 |
針對pd-l1之抗體分子及其用途
|
EP3212230B1
(en)
|
2014-10-29 |
2021-01-20 |
Seagen Inc. |
Dosage and administration of non-fucosylated anti-cd40 antibodies
|
US10570186B2
(en)
|
2014-11-05 |
2020-02-25 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors (CAR) to selectively target protein complexes
|
MA40921A
(fr)
|
2014-11-05 |
2017-09-12 |
Abbvie Stemcentrx Llc |
Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation
|
EA201791029A1
(ru)
|
2014-11-10 |
2017-12-29 |
Дженентек, Инк. |
Антитела против интерлейкина-33 и их применение
|
AU2015346205B2
(en)
|
2014-11-12 |
2021-07-29 |
Memorial Sloan Kettering Cancer Center |
Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof
|
US10813952B2
(en)
|
2014-11-14 |
2020-10-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors
|
US10100129B2
(en)
|
2014-11-21 |
2018-10-16 |
Bristol-Myers Squibb Company |
Antibodies against CD73 and uses thereof
|
CA2969714A1
(en)
|
2014-12-02 |
2016-06-09 |
Sadhak SENGUPTA |
Methods and compositions for treating cancer
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
PL3227432T3
(pl)
|
2014-12-05 |
2024-03-11 |
Memorial Sloan Kettering Cancer Center |
Chimeryczne receptory antygenowe ukierunkowane na antygen dojrzewania komórek b i ich zastosowania
|
SG11201704550XA
(en)
|
2014-12-05 |
2017-07-28 |
Memorial Sloan Kettering Cancer Center |
Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof
|
CN113683711A
(zh)
|
2014-12-05 |
2021-11-23 |
纪念斯隆-凯特琳癌症中心 |
靶向g-蛋白偶联受体的嵌合抗原受体及其用途
|
CA2969704C
(en)
|
2014-12-05 |
2023-05-02 |
City Of Hope |
Cs1 targeted chimeric antigen receptor-modified t cells
|
AR102918A1
(es)
|
2014-12-05 |
2017-04-05 |
Genentech Inc |
Anticuerpos anti-cd79b y métodos de uso
|
WO2016090385A1
(en)
|
2014-12-05 |
2016-06-09 |
Applied Stemcell, Inc. |
Site-directed crispr/recombinase compositions and methods of integrating transgenes
|
US20160319035A1
(en)
|
2014-12-05 |
2016-11-03 |
Scott Kendall Dessain |
Pdk1 binding molecules and uses thereof
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
BR112017012502B1
(pt)
|
2014-12-12 |
2020-09-15 |
Bluebird Bio, Inc. |
Polinucleotídeo, polipeptídeo de car codificado pelo dito polinucleotídeo, vetor compreendendo o dito polinucleotídeo, composição compreendendo o dito vetor e método para geração de uma célula imune efetora compreendendo um car
|
AU2015362748A1
(en)
|
2014-12-15 |
2017-04-27 |
Bellicum Pharmaceuticals, Inc. |
Methods for controlled elimination of therapeutic cells
|
CA2969384A1
(en)
|
2014-12-17 |
2016-06-23 |
Cellectis |
Inhibitory chimeric antigen receptor (icar or n-car) expressing non-t cell transduction domain
|
EP3233119A2
(en)
|
2014-12-18 |
2017-10-25 |
Bergen Teknologioverforing AS |
Anti-axl antagonistic antibodies
|
US11091532B2
(en)
|
2014-12-24 |
2021-08-17 |
Autolus Limited |
T cell which co-expresses a CD19 chimeric antigen receptor and a CD22 chimeric antigen receptor
|
IL303247A
(en)
|
2014-12-29 |
2023-07-01 |
Novartis Ag |
Methods for preparing cells expressing a chimeric receptor antigen
|
NL2014108B1
(en)
|
2015-01-09 |
2016-09-30 |
Aduro Biotech Holdings Europe B V |
Altered april binding antibodies.
|
US9765330B1
(en)
|
2015-01-09 |
2017-09-19 |
Nant Holdings Ip, Llc |
Compositions and methods for reduction of allograft recognition and rejection
|
WO2016115482A1
(en)
|
2015-01-16 |
2016-07-21 |
Novartis Pharma Ag |
Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
|
CA2968141C
(en)
|
2015-01-16 |
2020-08-04 |
Hsing-Mao CHU |
Molecular constructs with targeting and effector elements
|
CA2973964A1
(en)
|
2015-01-16 |
2016-07-21 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for ror1
|
CN105859890A
(zh)
|
2015-01-19 |
2016-08-17 |
西比曼生物科技(上海)有限公司 |
嵌合抗原受体及其基因和重组表达载体、工程化cd30靶向性的nkt细胞及其应用
|
EP3250611B1
(en)
|
2015-01-26 |
2021-04-21 |
The University of Chicago |
Car t-cells recognizing cancer-specific il 13r-alpha2
|
AR100680A1
(es)
|
2015-01-26 |
2016-10-26 |
Macrogenics Inc |
Anticuerpos anti-dr5 y moléculas que comprenden dominios de unión de dr5 de los mismos
|
WO2016120217A1
(en)
|
2015-01-26 |
2016-08-04 |
Cellectis |
Anti-hsp70 specific chimeric antigen receptors (cars) for cancer immunotherapy
|
WO2016122014A1
(ko)
|
2015-01-27 |
2016-08-04 |
한국생명공학연구원 |
자연살해세포의 대량생산 방법 및 상기 방법으로 수득된 자연살해세포의 항암제로서의 용도
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
GB201501936D0
(en)
|
2015-02-05 |
2015-03-25 |
Ucl Business Plc |
Signalling system
|
EP4134430A1
(en)
|
2015-02-06 |
2023-02-15 |
National University of Singapore |
Methods for enhancing efficacy of therapeutic immune cells
|
US10647778B2
(en)
|
2015-02-09 |
2020-05-12 |
University Of Florida Research Foundation, Incorporated |
Bi-specific chimeric antigen receptor and uses thereof
|
JP6895890B2
(ja)
|
2015-02-10 |
2021-06-30 |
ミネルバ バイオテクノロジーズ コーポレーション |
ヒト化抗muc1* 抗体
|
US11248058B2
(en)
|
2015-02-19 |
2022-02-15 |
University Of Florida Research Foundation, Inc. |
Chimeric antigen receptors and uses thereof
|
EP3261651B1
(en)
|
2015-02-27 |
2022-05-04 |
iCell Gene Therapeutics LLC |
Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
|
GB201503742D0
(en)
|
2015-03-05 |
2015-04-22 |
Ucl Business Plc |
Chimeric antigen receptor
|
KR20240013291A
(ko)
|
2015-03-09 |
2024-01-30 |
시나이 헬스 시스템 |
세포의 증식을 제어하기 위해 세포 분열 좌위를 사용하기 위한 도구 및 방법
|
KR20170137079A
(ko)
|
2015-03-11 |
2017-12-12 |
셀렉티스 |
그것들의 지속을 증가시키기 위한 동종이계 t 세포의 조작 및/또는 환자들 내로 이식 방법들
|
CA2979976A1
(en)
|
2015-03-17 |
2016-09-22 |
Memorial Sloan Kettering Cancer Center |
Anti-muc16 antibodies and uses thereof
|
US10738116B2
(en)
|
2015-03-19 |
2020-08-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Dual specific anti-CD22-anti-CD19 chimeric antigen receptors
|
WO2016154047A2
(en)
|
2015-03-20 |
2016-09-29 |
Memorial Sloan-Kettering Cancer Center |
Monoclonal antigen-binding proteins to intracellular oncogene products
|
US10800828B2
(en)
|
2015-03-26 |
2020-10-13 |
The Scripps Research Institute |
Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
|
CN106146666B
(zh)
|
2015-03-26 |
2019-09-06 |
科济生物医药(上海)有限公司 |
靶向cldn6的免疫效应细胞及其制备方法和应用
|
CA2981166A1
(en)
|
2015-03-27 |
2016-10-06 |
University Of Southern California |
Hla-g as a novel target for car t-cell immunotherapy
|
ES2904573T3
(es)
|
2015-03-27 |
2022-04-05 |
Univ Southern California |
Terapia con células T dirigida a LHR para el tratamiento de tumores sólidos
|
AU2016243126A1
(en)
|
2015-03-27 |
2017-11-02 |
University Of Southern California |
CAR T-cells for the treatment of B7-H4 expressing solid tumors
|
CN107427578A
(zh)
|
2015-03-27 |
2017-12-01 |
南克维斯特公司 |
用于治疗癌症的被遗传修饰的nk‑92细胞和单克隆抗体
|
RU2754041C2
(ru)
|
2015-04-03 |
2021-08-25 |
Еурека Терапьютикс, Инк. |
Конструкции, направленные на комплексы пептида afp/мнс, и виды их использования
|
US10881711B2
(en)
|
2015-04-06 |
2021-01-05 |
The General Hospital Corporation |
Anti-CSPG4 reagents and methods of treating cancer
|
US20180140602A1
(en)
|
2015-04-07 |
2018-05-24 |
Novartis Ag |
Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
|
SG11201708191XA
(en)
|
2015-04-08 |
2017-11-29 |
Novartis Ag |
Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
|
IL297223A
(en)
|
2015-04-13 |
2022-12-01 |
Pfizer |
Chimeric antigen receptors antigen-directed maturation of b cells
|
EP3283113A4
(en)
|
2015-04-15 |
2018-12-05 |
The California Institute for Biomedical Research |
Optimized pne-based chimeric receptor t cell switches and uses thereof
|
MX2017013247A
(es)
|
2015-04-15 |
2018-08-15 |
Prospect Chartercare Rwmc Llc D/B/A Roger Williams Medical Center |
Infusion arterial hepatica de linfocitos t car.
|
WO2016168769A1
(en)
|
2015-04-15 |
2016-10-20 |
The California Institute For Biomedical Research |
Chimeric receptor t cell switches for her2
|
JP7114457B2
(ja)
|
2015-04-17 |
2022-08-08 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
キメラ抗原受容体発現細胞の有効性および増殖を改善するための方法
|
JP7229768B2
(ja)
|
2015-04-23 |
2023-02-28 |
ヒーマロジックス プロプライエタリー リミテッド |
カッパ骨髄腫抗原キメラ抗原受容体およびその使用
|
WO2016172537A1
(en)
|
2015-04-23 |
2016-10-27 |
The Trustees Of The University Of Pennsylvania |
Compositions to disrupt protein kinase a anchoring and uses thereof
|
GB201507108D0
(en)
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic acid construct
|
HUE057720T2
(hu)
|
2015-05-04 |
2022-06-28 |
Cytomx Therapeutics Inc |
Aktiválható anti-CD71 antitestek és ezek alkalmazási eljárásai
|
WO2016179319A1
(en)
|
2015-05-04 |
2016-11-10 |
Cellerant Therapeutics, Inc. |
Chimeric antigen receptors with ctla4 signal transduction domains
|
RU2017142716A
(ru)
|
2015-05-08 |
2019-06-10 |
Еурека Терапьютикс, Инк. |
Конструкции, направленные на комплексы пептида hpv16-e7/мнс, и виды их использования
|
AU2016265845B2
(en)
|
2015-05-15 |
2020-10-08 |
City Of Hope |
Chimeric antigen receptor compositions
|
HUE051661T2
(hu)
|
2015-05-18 |
2021-03-29 |
Tcr2 Therapeutics Inc |
Készítmények és gyógyászati felhasználások a TCR újraprogramozására fúziós fehérjék felhasználásával
|
EP3298032A1
(en)
|
2015-05-18 |
2018-03-28 |
Bluebird Bio, Inc. |
Anti-ror1 chimeric antigen receptors
|
AU2016263513A1
(en)
|
2015-05-20 |
2017-11-23 |
Cellectis |
Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy
|
WO2016191246A2
(en)
|
2015-05-22 |
2016-12-01 |
Memorial Sloan-Kettering Cancer Center |
T cell receptor-like antibodies specific for a prame peptide
|
EP3098237B1
(en)
|
2015-05-28 |
2018-08-01 |
Universität Zu Köln |
Anti-toso chimeric antigen receptor and its use
|
SG10202008304TA
(en)
|
2015-05-29 |
2020-10-29 |
Bristol Myers Squibb Co |
Antibodies against ox40 and uses thereof
|
JP6979877B2
(ja)
|
2015-06-08 |
2021-12-15 |
デビオファーム インターナショナル, エス. アー. |
抗cd37イムノコンジュゲートおよび抗cd20抗体の組み合わせ
|
JP7269733B2
(ja)
|
2015-06-12 |
2023-05-09 |
レンティジェン・テクノロジー・インコーポレイテッド |
操作されたt細胞を用いて癌を処置するための方法
|
CN108473573A
(zh)
|
2015-06-29 |
2018-08-31 |
豪夫迈·罗氏有限公司 |
Ii型抗cd20抗体用于器官移植中
|
JP6403277B2
(ja)
|
2015-06-30 |
2018-10-10 |
オートモーティブエナジーサプライ株式会社 |
リチウムイオン二次電池の製造方法
|
EP3316908A4
(en)
|
2015-06-30 |
2019-03-06 |
Henlius Biotech Co., Ltd. |
VASCULAR ENDOTHELIAL GROWTH FACTOR ANTI-RECEPTOR 2 (VEGFR2) ANTIBODY
|
EP3971284B1
(en)
|
2015-07-29 |
2023-11-08 |
ONK Therapeutics Limited |
Modified natural killer cells and natural killer cell lines having increased cytotoxicity
|
US10166255B2
(en)
|
2015-07-31 |
2019-01-01 |
Regents Of The University Of Minnesota |
Intracellular genomic transplant and methods of therapy
|
BR112018002600A2
(pt)
|
2015-08-11 |
2018-10-23 |
Cellectis |
células para imunoterapia modificadas para direcionamento ao antígeno cd38 e para inativação do gene cd38
|
CA2997551A1
(en)
|
2015-09-04 |
2017-03-09 |
Memorial Sloan Kettering Cancer Center |
Immune cell compositions and methods of use
|
EP3347373A1
(en)
|
2015-10-10 |
2018-07-18 |
Intrexon Corporation |
Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
|
MX2018004546A
(es)
|
2015-10-16 |
2019-04-15 |
Univ Columbia |
Composiciones y métodos para la inhibicion de antígenos específicos de linaje.
|
EP3368689B1
(en)
|
2015-10-28 |
2020-06-17 |
The Broad Institute, Inc. |
Composition for modulating immune responses by use of immune cell gene signature
|
ES2953925T3
(es)
|
2015-11-04 |
2023-11-17 |
Fate Therapeutics Inc |
Ingeniería genómica de células pluripotentes
|
JP2018533363A
(ja)
|
2015-11-04 |
2018-11-15 |
フェイト セラピューティクス,インコーポレイテッド |
造血細胞分化を誘導するための方法および組成物
|
US10941381B2
(en)
|
2015-11-19 |
2021-03-09 |
Versiti Blood Research Institute Foundation, Inc. |
Method of manufacturing dual-specific T-cells for use in cancer immunotherapy
|
US11052111B2
(en)
|
2015-12-08 |
2021-07-06 |
Chimera Bioengineering, Inc. |
Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
|
CN108778314A
(zh)
|
2015-12-16 |
2018-11-09 |
沃尔特及伊莱萨霍尔医学研究院 |
Nk细胞中对细胞因子诱导的sh2蛋白的抑制
|
WO2017112784A1
(en)
|
2015-12-22 |
2017-06-29 |
The Trustees Of The University Of Pennsylvania |
Spycatcher and spytag: universal immune receptors for t cells
|
EA201891619A1
(ru)
|
2016-01-11 |
2019-02-28 |
Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити |
Химерные белки и способы регулирования экспрессии генов
|
KR102587132B1
(ko)
|
2016-03-04 |
2023-10-11 |
에디타스 메디신, 인코포레이티드 |
암 면역요법을 위한 crispr-cpf1-관련 방법, 조성물 및 구성성분
|
JP6592184B2
(ja)
|
2016-03-24 |
2019-10-16 |
富士フイルム株式会社 |
画像処理装置、画像処理方法、及び画像処理プログラム
|
IL303785A
(en)
|
2016-04-01 |
2023-08-01 |
Kite Pharma Inc |
Chimeric antigen and T cell receptors and methods of use
|
US20190161530A1
(en)
|
2016-04-07 |
2019-05-30 |
Bluebird Bio, Inc. |
Chimeric antigen receptor t cell compositions
|
KR20230107408A
(ko)
|
2016-07-29 |
2023-07-14 |
주노 쎄러퓨티크스 인코퍼레이티드 |
항-cd19 항체에 대한 항-이디오타입 항체
|
AU2017307610B2
(en)
|
2016-08-04 |
2023-10-05 |
Memorial Sloan-Kettering Cancer Center |
Cancer antigen targets and uses thereof
|
SG10201913583QA
(en)
|
2016-08-23 |
2020-02-27 |
Univ California |
Proteolytically cleavable chimeric polypeptides and methods of use thereof
|
EP3504223A4
(en)
|
2016-08-26 |
2020-03-25 |
Baylor College of Medicine |
CELLULAR ACTIVE CELL THERAPY CYTOKINE RECEPTORS
|
CN110520530A
(zh)
|
2016-10-18 |
2019-11-29 |
明尼苏达大学董事会 |
肿瘤浸润性淋巴细胞和治疗方法
|
WO2018072025A1
(en)
|
2016-10-19 |
2018-04-26 |
The Governing Council Of The University Of Toronto |
Cd133-binding agents and uses thereof
|
EP3529351A1
(en)
|
2016-10-19 |
2019-08-28 |
Cellectis |
Targeted gene insertion for improved immune cells therapy
|
GB201619876D0
(en)
|
2016-11-24 |
2017-01-11 |
Cambridge Entpr Ltd |
Controllable transcription
|
MX2019007840A
(es)
|
2016-12-30 |
2020-08-03 |
Celularity Inc |
Celulas asesinas naturales modificadas geneticamente.
|
EP3585426A4
(en)
|
2017-02-22 |
2020-11-25 |
Aleta Biotherapeutics Inc. |
COMPOSITIONS AND METHODS OF TUMOR TRANSDUCTION
|
AU2018225164A1
(en)
|
2017-02-22 |
2019-09-19 |
Aleta Biotherapeutics Inc. |
Compositions and methods for treatment of cancer
|
WO2018161038A1
(en)
|
2017-03-03 |
2018-09-07 |
Obsidian Therapeutics, Inc. |
Il12 compositions and methods for immunotherapy
|
US11629340B2
(en)
|
2017-03-03 |
2023-04-18 |
Obsidian Therapeutics, Inc. |
DHFR tunable protein regulation
|
WO2018165913A1
(zh)
|
2017-03-15 |
2018-09-20 |
南京凯地生物科技有限公司 |
靶向nkg2dl的特异性嵌合抗原受体及其car-t细胞以及它们的应用
|
CN110637083A
(zh)
|
2017-03-20 |
2019-12-31 |
华盛顿大学 |
细胞及其使用和制备方法
|
US11690873B2
(en)
|
2017-03-31 |
2023-07-04 |
Cellectis Sa |
Universal chimeric antigen receptor T cells specific for CD22
|
US10934336B2
(en)
|
2017-04-13 |
2021-03-02 |
The Trustees Of The University Of Pennsylvania |
Use of gene editing to generate universal TCR re-directed T cells for adoptive immunotherapy
|
US11980640B2
(en)
|
2017-05-15 |
2024-05-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bicistronic chimeric antigen receptors and their uses
|
AU2018270111B2
(en)
|
2017-05-18 |
2022-07-14 |
Modernatx, Inc. |
Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
|
JP2020524487A
(ja)
|
2017-06-07 |
2020-08-20 |
ザ ジェネラル ホスピタル コーポレイション |
キメラ抗原受容体を発現するt細胞
|
MA49403A
(fr)
|
2017-06-12 |
2021-03-24 |
Obsidian Therapeutics Inc |
Compositions de pde5 et méthodes d'immunothérapie
|
WO2019024979A1
(en)
*
|
2017-07-31 |
2019-02-07 |
Institute For Research In Biomedicine |
FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION
|
AU2018338192B2
(en)
|
2017-09-22 |
2022-03-03 |
Kite Pharma, Inc. |
Chimeric polypeptides and uses thereof
|
US20190091310A1
(en)
|
2017-09-26 |
2019-03-28 |
Stephen E. Wright |
Nonreleased il-12 for therapy of cancer
|
EA202090839A1
(ru)
|
2017-09-27 |
2021-02-04 |
Юниверсити Оф Саутерн Калифорния |
Новые платформы для костимуляции, новые конструкции car и другие улучшения для адаптивной клеточной терапии
|
EP3710471A1
(en)
|
2017-11-16 |
2020-09-23 |
Kite Pharma, Inc. |
Modified chimeric antigen receptors and methods of use
|
EP3720950A1
(en)
|
2017-12-05 |
2020-10-14 |
Celyad S.A. |
Reducing fratricide of immune cells expressing nkg2d-based receptors
|
MX2020005477A
(es)
|
2017-12-08 |
2020-11-06 |
Fate Therapeutics Inc |
Inmunoterapias con el uso de células efectoras potenciadas derivadas de ipsc.
|
CA3084553A1
(en)
|
2017-12-22 |
2019-06-27 |
Bluebird Bio, Inc. |
Multivalent chimeric antigen receptor
|
EP3728563A4
(en)
|
2017-12-22 |
2021-11-10 |
Fate Therapeutics, Inc. |
ENHANCED IMMUNE EFFECTIVE CELLS AND THEIR USE
|
AU2019216269A1
(en)
|
2018-01-30 |
2020-05-28 |
Cellectis |
Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen
|
WO2019157454A1
(en)
|
2018-02-11 |
2019-08-15 |
Memorial Sloan-Kettering Cancer Center |
Non-hla restricted t cell receptors and uses thereof
|
EP3752531A1
(en)
|
2018-02-14 |
2020-12-23 |
Kite Pharma, Inc. |
Anti-idiotypic antibodies directed to the antigen-binding portion of an bcma-binding molecule
|
KR102618231B1
(ko)
|
2018-02-16 |
2023-12-28 |
카이트 파마 인코포레이티드 |
변형된 만능성 줄기 세포, 및 제조 및 사용 방법
|
AU2019243315A1
(en)
|
2018-03-29 |
2020-09-24 |
Fate Therapeutics, Inc. |
Engineered immune effector cells and use thereof
|
US20210309713A1
(en)
|
2018-04-04 |
2021-10-07 |
Daren Biotech Limited |
Chimeric Antigen Receptor and Method for Treating Cancers
|
US20210147922A1
(en)
|
2018-04-18 |
2021-05-20 |
Altius Institute For Biomedical Sciences |
Methods for assessing specificity of cell engineering tools
|
CA3097648A1
(en)
|
2018-04-18 |
2019-10-24 |
Altius Institute For Biomedical Sciences |
Animal pathogen-derived polypeptides and uses thereof for genetic engineering
|
CN108531458A
(zh)
|
2018-04-27 |
2018-09-14 |
赛诺(深圳)生物医药研究有限公司 |
治疗肿瘤的基因工程自然杀伤细胞产品
|
US20210230548A1
(en)
|
2018-05-03 |
2021-07-29 |
Board Of Regents, The University Of Texas System |
Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade
|
EP3790629A1
(en)
|
2018-05-11 |
2021-03-17 |
CRISPR Therapeutics AG |
Methods and compositions for treating cancer
|
CN112839666A
(zh)
|
2018-05-14 |
2021-05-25 |
因达普塔治疗公司 |
具有增强的抗体导向免疫应答的人自然杀伤细胞亚群
|
JP2021523741A
(ja)
|
2018-05-14 |
2021-09-09 |
ウェアウルフ セラピューティクス, インコーポレイテッド |
活性化可能なインターロイキン12ポリペプチド及びその使用方法
|
GB201807870D0
(en)
|
2018-05-15 |
2018-06-27 |
Autolus Ltd |
A CD79-specific chimeric antigen receptor
|
CN112119096B
(zh)
|
2018-05-15 |
2024-04-30 |
奥托路斯有限公司 |
嵌合抗原受体
|
KR102617238B1
(ko)
|
2018-05-22 |
2023-12-21 |
난트퀘스트, 인크. |
Fc-엡실론 car(fc-epsilon car)
|
US20200054675A1
(en)
|
2018-06-01 |
2020-02-20 |
Washington University |
Suppression of cytokine release syndrome in chimeric antigen receptor cell therapy
|
EP3806871A4
(en)
|
2018-06-12 |
2022-02-23 |
The Regents of the University of California |
SINGLE-CHAIN BISPECIFIC CHEMICAL ANTIGEN RECEPTORS FOR THE TREATMENT OF CANCER
|
EP3581200A1
(en)
|
2018-06-13 |
2019-12-18 |
GEMoaB Monoclonals GmbH |
Reversed universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
|
WO2019241688A1
(en)
|
2018-06-14 |
2019-12-19 |
Bluebird Bio, Inc. |
Cd79b chimeric antigen receptors
|
MX2020013977A
(es)
|
2018-06-22 |
2021-06-15 |
Kite Pharma Inc |
Proteínas quiméricas transmembrana y usos de las mismas.
|
WO2020000035A1
(en)
|
2018-06-25 |
2020-01-02 |
Peter Maccallum Cancer Institute |
Modified t cells and uses thereof
|
WO2020006126A1
(en)
|
2018-06-27 |
2020-01-02 |
Altius Institute For Biomedical Sciences |
Nucleic acid binding domains and methods of use thereof
|
US20210205362A1
(en)
|
2018-07-05 |
2021-07-08 |
H. Lee Moffitt Cancer Center and Research Inc. |
Car t cells that target b-cell antigens
|
WO2020010235A1
(en)
|
2018-07-05 |
2020-01-09 |
H. Lee Moffitt Cancer Center And Research Institute Inc. |
Car t cells that target b-cell antigens
|
AU2019306628A1
(en)
|
2018-07-20 |
2021-02-11 |
Surface Oncology, Inc. |
Anti-CD112R compositions and methods
|
AU2019312008A1
(en)
|
2018-07-26 |
2021-03-18 |
Kyoto University |
Method for generating cells into which an exogenous antigen receptor is introduced
|
EP3829605A4
(en)
|
2018-08-01 |
2022-10-19 |
ImmunityBio, Inc. |
QUADRICISTRONIC SYSTEM WITH A HOMING RECEPTOR OR A CYTOKINE AND A CHIMERIC ANTIGEN RECEPTOR FOR GENETIC MODIFICATION OF IMMUNOTHERAPIES
|
US20220054544A1
(en)
|
2018-09-21 |
2022-02-24 |
Harpoon Therapeutics, Inc. |
Conditionally active receptors
|
EP3873939A4
(en)
|
2018-10-30 |
2022-12-07 |
Board of Regents, The University of Texas System |
ANTI-CD79B ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE
|
JP7092404B2
(ja)
|
2018-10-31 |
2022-06-28 |
イミュニティーバイオ、インコーポレイテッド |
Pd-l1キメラ抗原受容体を発現するnk細胞によるpd-l1陽性悪性腫瘍の排除
|
SG11202104524YA
(en)
|
2018-11-01 |
2021-05-28 |
Gracell Biotechnologies Shanghai Co Ltd |
Compositions and methods for t cell engineering
|
US11547727B2
(en)
|
2018-11-06 |
2023-01-10 |
Immunitybio, Inc. |
Chimeric antigen receptor-modified NK-92 cells
|
US20220127373A1
(en)
|
2018-11-08 |
2022-04-28 |
The Regents Of The University Of California |
Systems and methods for targeting cancer cells
|
WO2020112669A1
(en)
|
2018-11-26 |
2020-06-04 |
Nantkwest, Inc. |
Il-2 dependent nk-92 cells with stable fc receptor expression
|
US20220047634A1
(en)
|
2018-11-30 |
2022-02-17 |
Dana-Farber Cancer Institute, Inc. |
Chimeric antigen receptor factories and methods of use thereof
|
KR20210099601A
(ko)
|
2018-12-02 |
2021-08-12 |
페이트 세러퓨틱스, 인코포레이티드 |
향상된 iPSC 유래 효과기 세포를 사용한 면역요법
|
US20220056092A1
(en)
|
2018-12-11 |
2022-02-24 |
Obsidian Therapeutics, Inc. |
Membrane bound il12 compositions and methods for tunable regulation
|
WO2020124021A1
(en)
|
2018-12-13 |
2020-06-18 |
The General Hospital Corporation |
Chimeric antigen receptors targeting cd79b and cd19
|
CN111355871A
(zh)
|
2018-12-21 |
2020-06-30 |
三赢科技(深圳)有限公司 |
镜头模组及其组装方法
|
AU2020207962A1
(en)
|
2019-01-18 |
2021-07-22 |
University Of Southern California |
Methods and compositions to improve the safety and efficacy of cellular therapies
|
US20220143084A1
(en)
|
2019-02-15 |
2022-05-12 |
Editas Medicine, Inc. |
Modified natural killer (nk) cells for immunotherapy
|
WO2020172177A1
(en)
|
2019-02-18 |
2020-08-27 |
Memorial Sloan-Kettering Cancer Center |
Combinations of multiple chimeric antigen receptors for immunotherapy
|
WO2020176678A1
(en)
*
|
2019-02-26 |
2020-09-03 |
Twist Bioscience Corporation |
Variant nucleic acid libraries for glp1 receptor
|
CN113906133A
(zh)
|
2019-04-11 |
2022-01-07 |
菲特治疗公司 |
工程改造的iPSC和免疫效应细胞中的CD3重建
|
JP2022526841A
(ja)
|
2019-04-12 |
2022-05-26 |
フェインズ セラピューティクス,インコーポレーテッド |
ヒト化抗葉酸受容体1キメラ抗原受容体及びその使用
|
US20210069242A1
(en)
|
2019-04-18 |
2021-03-11 |
Dmitry Dmitrievich Genkin |
Reprogramming of polymorphonuclear leukocytes
|
SG11202111130SA
(en)
|
2019-04-30 |
2021-11-29 |
Senti Biosciences Inc |
Chimeric receptors and methods of use thereof
|
WO2020247392A1
(en)
|
2019-06-04 |
2020-12-10 |
Nkarta, Inc. |
Combinations of engineered natural killer cells and engineered t cells for immunotherapy
|
CN114269372A
(zh)
|
2019-06-27 |
2022-04-01 |
克里斯珀医疗股份公司 |
嵌合抗原受体t细胞和nk细胞抑制剂用于治疗癌症的用途
|
WO2021015997A1
(en)
|
2019-07-15 |
2021-01-28 |
President And Fellows Of Harvard College |
Methods and compositions for gene delivery
|
CN114222815A
(zh)
|
2019-07-23 |
2022-03-22 |
记忆疗法公司 |
Suv39h1缺陷的免疫细胞
|
EP4017508A1
(en)
|
2019-08-23 |
2022-06-29 |
Sana Biotechnology, Inc. |
Cd24 expressing cells and uses thereof
|
CN114729325A
(zh)
|
2019-09-06 |
2022-07-08 |
克里斯珀医疗股份公司 |
在培养物中具有改善的持久性的基因工程化t细胞
|
CN114514246A
(zh)
|
2019-10-07 |
2022-05-17 |
埃克斯-马赛大学 |
对nectin-4具有特异性的抗体及其用途
|
WO2021076427A1
(en)
|
2019-10-15 |
2021-04-22 |
The Regents Of The University Of California |
TRANSPLANTED CELL PROTECTION VIA Fc SEQUESTRATION
|
WO2021077117A1
(en)
|
2019-10-17 |
2021-04-22 |
Fate Therapeutics, Inc. |
Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof
|
CA3155246A1
(en)
|
2019-10-21 |
2021-04-29 |
Sandro MATOSEVIC |
Engineered natural killer cells and methods for using the same in immunotherapy and autophagy inhibition techniques
|
BR112022008215A2
(pt)
|
2019-10-31 |
2022-07-12 |
Res Inst Nationwide Childrens Hospital |
Geração de células nk humanas primárias e expandidas knock-out de cd38
|
EP4054598A1
(en)
|
2019-11-05 |
2022-09-14 |
City of Hope |
Generation of chimeric antigen receptor modified t cells from stem cells and therapeutic uses thereof
|
AR120470A1
(es)
|
2019-11-13 |
2022-02-16 |
Crispr Therapeutics Ag |
Métodos para fabricar células t car
|
CN114845730A
(zh)
|
2019-11-13 |
2022-08-02 |
克里斯珀医疗股份公司 |
使用靶向cd70的基因工程化t细胞用于造血细胞恶性肿瘤的疗法
|
MX2022005983A
(es)
|
2019-11-18 |
2022-09-07 |
Janssen Biotech Inc |
Receptores del antígeno quimérico anti-cd79, células car-t, y usos de estos.
|
IL293946A
(en)
|
2019-12-18 |
2022-08-01 |
Editas Medicine Inc |
Transgenic cells for therapy
|
KR20220142433A
(ko)
|
2020-01-17 |
2022-10-21 |
사나 바이오테크놀로지, 인크. |
유전자 발현 조절용 안전 스위치
|
US20210254005A1
(en)
|
2020-01-23 |
2021-08-19 |
Kangstem Biotech Co., Ltd. |
Off-the-shelf stem cell and immune cell, and a pharmaceutical composition including the same
|
US11230699B2
(en)
|
2020-01-28 |
2022-01-25 |
Immunitybio, Inc. |
Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
|
WO2021154218A1
(en)
|
2020-01-28 |
2021-08-05 |
Nantkwest, Inc. |
Chimeric antigen receptor-modified nk-92 cells targeting egfr super-family receptors
|
CN115916968A
(zh)
|
2020-05-04 |
2023-04-04 |
爱迪塔斯医药公司 |
通过必需基因敲入进行选择
|
WO2021234662A1
(en)
|
2020-05-21 |
2021-11-25 |
Crispr Therapeutics Ag |
Genetically engineered car t cells that secrete interleukin-12 and therapeutic uses thereof
|
MX2022015586A
(es)
|
2020-06-12 |
2023-03-15 |
Nkarta Inc |
Linfocitos citolíticos naturales modificados genéticamente para inmunoterapia de cáncer dirigida a cd70.
|
IL299106A
(en)
*
|
2020-06-19 |
2023-02-01 |
Fate Therapeutics Inc |
Combination of effector immune cells, derived from induced pluripotent stem cells for use in immunotherapy
|
CN116113689A
(zh)
|
2020-08-14 |
2023-05-12 |
凯德药业股份有限公司 |
改善免疫细胞功能
|
MX2023001588A
(es)
|
2020-08-17 |
2023-05-03 |
Bicycletx Ltd |
Conjugados biciclo específicos para nectina-4 y usos de estos.
|
EP4225373A1
(en)
|
2020-10-07 |
2023-08-16 |
Dren Bio, Inc. |
Anti-dectin-1 antibodies and methods of use thereof
|
JP2023545992A
(ja)
|
2020-10-09 |
2023-11-01 |
フェイト セラピューティクス,インコーポレイティド |
操作されたiPSC及び装備された免疫エフェクター細胞
|
EP4232566A1
(en)
|
2020-10-22 |
2023-08-30 |
Lyell Immunopharma, Inc. |
Chimeric activation receptors
|
EP4232465A1
(en)
|
2020-10-26 |
2023-08-30 |
Memorial Sloan Kettering Cancer Center |
Cells with cd70 knockout and uses for immunotherapy
|
KR20230096110A
(ko)
|
2020-11-04 |
2023-06-29 |
페이트 세러퓨틱스, 인코포레이티드 |
고형 종양을 표적화하는 멀티플렉스화된 조작 iPSC 및 면역 효과기 세포
|